Article references (15 references )


  1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation. 1995; 92(4): 785-789. PubMed | Google Scholar

  2. Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004; 116 (1): 14-18. PubMed | Google Scholar

  3. Greaves SC, Roche AH, Neutze JM, Whitlock RM, Veale AM. Inheritance of hypertrophic cardiomyopathy: a cross sectional and M mode echocardiographic study of 50 families. Br Heart J. 1987; 58(3): 259-266. PubMed | Google Scholar

  4. Maron BJ, Nichols PF, Pickle LW, Wesley YE, Mulvihill JJ. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol. 1984; 53(8): 1087-1094. PubMed | Google Scholar

  5. Maron BJ. American College of Cardiology/European Society of Cardiology: clinican expert consensus document on hypertrophic cardiomyopathy. Eur Heart J. 2003; 24: 1965-1991. Google Scholar

  6. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the European Society of Cardiology Committee for Practice Guidelines. J American Coll Cardiol. 2003; 42(9): 1687-1713. PubMed | Google Scholar

  7. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. J Thorac Cardiovasc Surg. 2011; 142(6): 1303-1338. PubMed | Google Scholar

  8. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014; 35(39): 2733-2779. PubMed | Google Scholar

  9. Camenzind E, Martin W, Sigwart U. La cardiomyopathie hypertrophique: options thérapeutiques. Med Hyg. 2002; 60(2393): 1047-1056. Google Scholar

  10. Malergue MC. Traitement de la cardiomyopathie hypertrophique obstructive par alcoolisation septale: quelles indications. MT cardio. 2006; 2(2): 235-247. Google Scholar

  11. Sigwart U. Non-surgical myocardial reduction for patients with hypertrophic obstructive cardiomyopathy. Eur Heart J. 2001; 3(suppl): 38-42. Google Scholar

  12. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part II. Circulation. 2001; 104(18): 2249-2252. PubMed | Google Scholar

  13. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003; 42(5): 873-879. PubMed | Google Scholar

  14. Nishimura RA, Holmes Jr DR. Hypertrophic obstructive cardiomyopathy. N Engl J Med. 2004; 350(13): 1320-1327. PubMed | Google Scholar

  15. O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014; 35(30): 2010-2020. PubMed | Google Scholar